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Proteinase-Activated Receptor-2 (PAR2): A Tumor
Suppressor in Skin Carcinogenesis
Anke Rattenholl1, Stephan Seeliger2, Jo¨rg Buddenkotte1, Margarete Scho¨n3,4, Michael P. Scho¨n3,4,
Sonja Sta¨nder1, Nathalie Vergnolle5 and Martin Steinhoff1
The proteinase-activated receptor PAR2 has been demonstrated to modulate tumor growth, invasion and
metastasis in various tissues. However, the role of PAR2 in cutaneous cancerogenesis is still unknown. Here we
could show a protective role of PAR2 in the development of epidermal skin tumors: we established a mouse skin
tumor model using chemically induced carcinogenesis. Tumors started to appear after eight weeks. After 13
weeks, PAR2-deficient mice showed a significantly increased number of skin tumors (14 per animal on the
average) in contrast to the wild type (eight tumors per mouse). Analysis of possible signal transduction
pathways activated upon PAR2 stimulation in HaCaT keratinocytes showed an involvement of extracellular
signal-regulated kinase 1/2 and profound epidermal growth factor receptor transactivation, leading to secretion
of the tumor-suppressing factor transforming growth factor-b1. Thus, our results provide early experimental
evidence for a tumor-protective role of PAR2.
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INTRODUCTION
Several observations suggest an important role of serine
proteinases in regulating skin homeostasis, dermo-epidermal
barrier function, cell differentiation, and tumor growth
(reviewed in Ossovskaya and Bunnett, 2004). Recent findings
clearly indicate that some serine proteinases, apart from their
function to activate proteolytic enzyme cascades or to degrade
proteins, are known to act as signal molecules via specific
cleavage of certain seven-transmembrane domain G-protein-
coupled receptors, the proteinase-activated receptors (PARs).
So far, four members of this receptor class are known. PAR1,
PAR3, and PAR4 are activated by thrombin, whereas PAR2 is
stimulated by several trypsin-like enzymes including trypsin
and mast-cell tryptase (reviewed in Steinhoff et al., 2005). In
addition, recent results show that PAR1 can be also activated
by matrix metalloproteinase-1 (MMP-1) (Boire et al., 2005).
PAR2 was mostly reported to play a growth-promoting role
in tumors derived from numerous tissues (Darmoul et al.,
2004; Ge et al., 2004; Hjortoe et al., 2004; Jikuhara et al.,
2004; Shi et al., 2004; Shimamoto et al., 2004). In the skin,
the receptor is strongly expressed by human keratinocytes
(Santulli et al., 1995; Derian et al., 1997; Hou et al., 1998;
Steinhoff et al., 1999; Algermissen et al., 2000) and appears
to play an important role in cutaneous homeostasis and tissue
repair (reviewed in Rattenholl and Steinhoff, 2003). PAR2
agonists increase [Ca2þ ]i (Santulli et al., 1995), presumably
resulting in inhibition of growth and differentiation of
keratinocytes (Derian et al., 1997). In vivo, PAR2 on
epidermal keratinocytes could be activated by an autocrine
mechanism via keratinocyte-derived trypsinogen IV that was
reported to activate PAR2 and PAR4 (Cottrell et al., 2004).
Although PAR2 is highly expressed by human keratino-
cytes, its role in human skin carcinogenesis is still unknown.
Therefore the aim of this study was (a) to investigate the
development of chemically induced skin tumors in PAR2-
deficient mice compared to the wild-type, (b) to examine
potential signal transduction pathways involved in PAR2-
mediated suppression of skin cancerogenesis using the
keratinocyte cell line HaCaT, and (c) to identify possible
tumor suppressing factors released after stimulation of PAR2.
RESULTS
Increased skin carcinogenesis in PAR2-deficient mice
To investigate a possible tumor suppressing effect of PAR2
in epidermal keratinocytes, chemically induced skin
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carcinogenesis was monitored for 13 weeks in PAR2-deficient
and wild-type mice. Whereas only few papillomas could be
observed in wild-type animals, PAR2-deficient mice had
developed numerous epidermal skin tumors. A quantitative
analysis of tumor numbers is shown in Figure 1. In both
groups, tumors started to appear after seven weeks. Two
weeks later, all mice had developed papillomas (Figure 1a).
However, after 13 weeks, the PAR2-deficient animals had
formed a markedly enhanced number of tumors as compared
to the wild-type animals (Figure 1b): these PAR2-deficient
mice exhibited more than 14 tumors per mouse on the
average. In contrast, wild-type animals had formed only eight
epidermal skin tumors (Figure 1c). Mere application of the
vehicle (acetone/olive oil mixture) after 7,12-dimethylbenz-
[a]anthracene (DMBA) treatment did not lead to macroscopic
tumor formation (data not shown).
Histological analysis of tumor sections in both groups
showed that all tumors were benign papillomas, characteri-
zed by marked papillary hyperplasia and thickening of the
epidermis in contrast to the unaffected skin.
Analysis of epidermal cell differentiation in papillomas of
PAR2-deficient mice
As skin carcinogenesis is associated with keratinocyte
transformation, the differentiation of epidermal keratinocytes
in papillomas of wild-type and PAR2-deficient mice was
analyzed by immunohistochemistry using representative
marker proteins. Keratin 10 (K10), an early marker for
keratinocyte differentiation (Huitfeldt et al., 1991), was
expressed in suprabasal keratinocytes to the same extent in
normal skin sections of both genotypes (Figure 2a, b).
Moreover, K10 immunoreactivity was reduced to a compar-
able degree in papillomas derived from both wild-type and
PAR2-deficient animals: all tumors examined exhibited
regions with a downregulation or even absence of K10.
Two examples are displayed in Figure 2c, d. However, the
number of K10-positive basal keratinocytes was slightly
enhanced in wild-type papillomas (Figure 2i). Loricrin, a
marker for late terminal keratinocyte differentiation (Mehrel
et al., 1990) could be found in the granular layers of normal
skin (Figure 2e, f) and in tumors of PAR2-deficient
mice (Figure 2g, h). No differences in loricrin expression
were observed in wild-type and PAR2-deficient papillomas
(Figure 2j).
Investigation of tumor angiogenesis and infiltration with
inflammatory cells in papillomas
Next, the presence of blood vessels in the tumors was
analyzed by immunohistochemistry using the marker CD31
(platelet/endothelial cell adhesion molecule-1). As expected,
numerous blood vessels could be found in papillomas of both
genotypes (Figure 3a, b). However, angiogenesis seemed to
be slightly upregulated in PAR2-deficient papillomas (Figure
3c) compared to wild-type tumors: when counting the large
vessels (X30 mm in diameter), PAR2-deficient tumors con-
tained 85 vessels per mm2 subbasal area compared to only 51
in the wild-type controls (Figure 3c).
To assess the infiltration of papillomas in both genotypes
by inflammatory cells (macrophages and granulocytes), the
marker CD11b (Mac-1a) was used. No difference could be
found in the tumors of both genotypes: all papillomas
analyzed showed a comparable degree of infiltration with
CD11b-positive cells (Figure 3d). Most of these cells could be
detected in the mesenchyme. However, some of them could
a b120
100
80
60
40
20
0
Weeks
2 4 6 8 10 12 14
Weeks
2 4 6 8 10 12 14
Pe
rc
en
ta
ge
 o
f m
ice
 
w
ith
 tu
m
or
s
c 18
16
14
12
10
8
6
4
2
0
Weeks
2 4 6 8 10 12 14
160
140
120
100
80
60
40
20
0
To
ta
l n
um
be
r o
f t
um
or
s
Av
er
ag
e 
nu
m
be
r o
f t
um
or
s
pe
r m
ou
se
*
Figure 1. Chemically induced tumor formation is promoted in PAR2-deficient mice. (a) Tumors started to develop after seven weeks. After nine weeks,
all animals were carrying at least one papilloma. (b, c) After 13 weeks, PAR2-deficient mice had developed a total of 143 papillomas (14 on the average per
animal) compared to only 83 (mean: eight per mouse) in the wild-type controls (n¼10 for each group; *Pp0.05).
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also be found in the epidermis, in the vicinity of the basement
membrane (not shown).
Apoptosis is not decreased in papillomas of PAR2-deficient mice
Paraffin sections obtained from PAR2
/ and wild-type
papillomas were screened for keratinocytes that underwent
apoptosis. Apoptotic cells were visualized by TUNEL
staining (Scho¨n et al, 2004). Some apoptotic cells could be
observed at the border to the granular layer in both genotypes
(Figure 4a, b). The apoptotic rate was low in both groups.
Activation of PAR2 leads to extracellular signal-regulated kinase
1/2 phosphorylation in cultured HaCaT keratinocytes
Next, possible signal transduction pathways activated upon
PAR2 stimulation in HaCaT keratinocytes, an immortalized
human keratinocyte cell line, were studied. HaCaT keratino-
cytes produce PAR1, PAR2, and PAR4 mRNAs (unpublished
results). Cells were serum-starved for 24 hours before the
addition of activating peptide (SLIGKV-NH2). After certain
incubation times, cells were lysed and probed for phosphor-
ylation of extracellular signal-regulated kinase 1/2 (ERK1/2)
by immunoblotting. Indeed, as soon as 5 minutes after
addition of PAR2-AP, activation of ERK1/2 could be observed
(Figure 5a). Phosphorylation decreased after 30 minutes but
could be detected up to 4 hours after stimulation of PAR2. In
contrast to the positive control obtained with sorbitol, no
activation of the p38 pathway after stimulation of HaCaT
cells with the PAR2-activating peptide could be observed
(Figure 5b).
PAR2 stimulation causes EGFR transactivation in HaCaT
keratinocytes
PAR2-mediated ERK1/2 phosphorylation in HaCaT keratino-
cytes involved transactivation of the EGFR because ERK1/2
activation was completely abolished in the presence of the
specific EGFR tyrosine kinase inhibitor PD153035 (Figure
6a). Next, we seeked to inhibit PAR2-dependent EGFR
transactivation on HaCaT keratinocytes using several metal-
loproteinase inhibitors: MMP inhibitor II is a potent inhibitor
of MMP-1, -3, -7, and –9; MMP inhibitor III inhibits MMP-1,
-2, -3, -7, and -13; o-phenanthroline is an unspecific
metalloproteinase inhibitor that acts via removal of the zinc
ion from the catalytic site; tumor necrosis factor-a protease
inhibitor-1 (TAPI-1) is an inhibitor for the membrane-bound
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Figure 2. Analysis of keratinocyte differentiation in mouse papillomas.
(a, b) Immunoreactivity for the differentiation marker K10 in normal skin.
(c, d) Staining for K10 in papillomas. Tumors of both genotypes show regions
with absent or low immunoreactivity for K10 (arrowheads). (e, f) Expression of
loricrin, a marker for late terminal keratinocyte differentiation, in normal skin.
(g, h) Staining for loricrin in mouse tumors. (i) Quantitative analysis of K10
expression in basal keratinocytes. WT papillomas contain a somewhat larger
number of K10-positive basal cells (n¼7 WT papillomas from six individual
mice; n¼ 9 PAR2-deficient papillomas obtained from eight animals).
(j) Comparable thickness of the loricrin-positive cell layer in tumors of both
genotypes (n¼ 7 WT papillomas from six mice; n¼10 PAR2-deficient tumors
obtained from eight animals). Bar¼100 mm.
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Figure 3. Analysis of angiogenesis and infiltration with inflammatory cells in
mouse papillomas. Immunoreactivity for the endothelial cell marker CD31 in
a (a) WT and (b) PAR2
/ papilloma. Bar¼ 100mm. (c) Only vessels with a
diameterX30mm were taken for the quantitative analysis of blood vessel
formation: PAR2-deficient mouse papillomas contain a slightly larger number
of large blood vessels compared to the wild-type (n¼7 WT tumors from seven
animals; n¼ 10 PAR2-deficient papillomas from eight mice). (d) Comparable
infiltration with CD11b-positive inflammatory cells in tumors of both
genotypes (n¼10 WT tumors from seven individual mice; n¼ 8
PAR2-deficient papillomas from six animals).
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metalloproteinase tumor necrosis factor-a converting enzyme
(TACE/ADAM17) which belongs to the ADAM (a disintegrin
and metalloproteinase) family of sheddases (Vincent et al.,
2001). Signal inhibition was again assessed by analysis of
ERK1/2 phosphorylation. Indeed, all inhibitors strongly
inhibited ERK1/2 phosphorylation, indicating that tumor
necrosis factor-a converting enzyme and maybe other
sheddases provoke shedding of EGFR ligands after activation
of PAR2 (Figure 6b, c).
PAR2 activation induces the release of the tumor suppressor
TGF-b1 from HaCaT keratinocytes
To investigate further a possible production of tumor
suppessing factors after EGFR transactivation on HaCaT
keratinocytes, the secretion of TGF-b1 was assessed after
stimulation with either trypsin or the PAR2 agonist trans-
cinnamoyl-LIGRLO-NH2 (tc-AP) (Roy et al., 1998), which is
more stable compared to the other activating peptide used in
this study (Figure 7). After 4 days of activation, the TGF-b1
concentration in the medium was increased about 6.1-fold in
the presence of tc-AP, as compared to the unstimulated
control. When HaCaT cells were stimulated with trypsin, the
TGF-b1 content was increased 3.8-fold. Next, secretion of
TGF-b1 was analyzed after inhibition of the ERK signal
transduction pathway. Mitogen-activated protein kinase
(MAPK) kinase-1 (MEK1) is a kinase upstream of ERK1/2.
Indeed, preincubation of the HaCaT cells with the MEK1
inhibitor PD98059 led to a significant inhibition of TGF-b1
secretion in the presence of trypsin. Here, the TGF-b1
concentration in the medium reached almost the level of
the negative control. Thus, TGF-b1 secretion mediated by
trypsin was fully dependent on PAR2-mediated EGFR
transactivation. Interestingly, TGF-b1 secretion provoked by
the agonist tc-AP was only insignificantly inhibited by the
MEK1 inhibitor.
DISCUSSION
In this study, we demonstrate for the first time a role for PAR2
as an inhibitor of the development in keratinocyte-derived
skin tumors in vivo. In contrast, this receptor was mostly
reported to promote proliferation of cells, for example
astrocytes (Wang et al., 2002) and various cancer cells
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Figure 4. Apoptotic keratinocytes in mouse papillomas (TUNEL assay).
Both WT and PAR2-deficient papillomas exhibit a comparable, low rate of
apoptosis. (a) WT papilloma. Few apoptotic cells can be found adjacent to the
granular layer (b) PAR2-deficient tumor. Some keratinocytes undergoing
apoptosis can be detected. (c) Negative control (PAR2
/ papilloma).
(d) Positive control (PAR2-deficient papilloma). Arrowheads denote apoptotic
cells. (a–c) Bar¼ 50 mm. (d) Bar¼ 100mm.
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not p38. (a) Cells were stimulated with 104 M PAR2-AP for up to four hours.
As soon as five minutes after addition of the peptide, phosphorylation of
ERK1/2 can be observed. ERK1/2 activation diminishes after 30 minutes.
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of p38. In contrast, p38 is not phosphorylated after activation of PAR2 with the
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Figure 6. Stimulation of PAR2 is followed by EGFR transacivation.
(a) PAR2-induced ERK1/2 phosphorylation is nearly completely abolished in
the presence of the EGFR kinase inhibitor PD153035. (b, c) PAR2-triggered
EGFR transactivation in HaCaT keratinocytes is mediated by
metalloproteinase activity: phosphorylation of ERK1/2 is inhibited
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4 M);
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(Jikuhara et al., 2004; Shi et al., 2004; Shimamoto et al.,
2004; Wilson et al., 2004). However, in agreement with our
results, others found that trypsinogen expression was down-
regulated in esophageal squamous-cell carcinomas and
certain gastric carcinomas (Yamashita et al., 2003). More-
over, in these gastric carcinomas, PAR2 expression was also
markedly reduced. In addition, other studies suggested a role
of PAR2 as a negative regulator in human pancreatic tumor
growth (Kaufmann et al., 1998). Okamoto et al. (2001)re-
ported that a human glioblastoma cell line produced both
PAR1 and PAR2. In the presence of a PAR2 agonist, cell
proliferation was markedly inhibited, whereas a PAR1 agonist
was not able to exert this effect. In conclusion, these findings
point to a tumor-suppressing role of PAR2 only in certain
tissues.
PAR1 and PAR2 modulate keratinocyte growth and
differentiation in cultured human keratinocytes (Derian
et al., 1997; Algermissen et al., 2000). Although PAR1
induces growth and proliferation in primary human kerati-
nocytes, PAR2 inhibits proliferation and differentiation.
To elucidate further these notions, mice deficient in PAR2
as well as wild-type controls were subjected to a two-stage
chemical skin carcinogenesis standard protocol. Although
both groups of animals showed similar latency periods, that is
tumor growth was detectable after seven weeks in both
groups, PAR2-deficient mice indeed developed a significantly
increased number of tumors as compared to the wild-type
counterparts.
Epithelial skin carcinogenesis is associated with loss of
keratinocyte differentiation (Jeon et al., 2004). Comparison of
early and late terminal keratinocyte differentiation by
utilizing the marker K10 (Huitfeldt et al., 1991) and loricrin
(Mehrel et al., 1990), respectively, showed that no differences
in loricrin expression could be detected but a slight increase
in K10-positive basal keratinocytes in wild-type papillomas. It
is known that the expression of K10 in the basal layer of the
epidermis inhibits cell proliferation and prevents skin
tumorigenesis (Santos et al., 2002). In contrast, loss of K10
leads to decreased tumor formation in mice due to increased
keratinocyte turnover (Reichelt et al., 2004). In this study, all
papillomas investigated showed regions with a downregula-
tion or even absence of K10 immunoreactivity in suprabasal
epidermal layers.
Several groups have shown that inflammatory mast cells
are able to affect angiogenesis in epidermal skin tumor
development (Coussens et al., 1999; Moore et al., 1999).
Immunohistochemical analysis of papillomas obtained
from PAR2-deficient and wild-type mice using the marker
CD11b, which stains mast cells and other inflammatory cells,
did not show any differences between PAR2
/ and PAR2
þ /þ
animals. In addition, immunoreactivity for CD31, a marker
for blood vessels, in PAR2-deficient and wild-type mice was
analyzed. For a more convenient analysis, only large vessels
with a diameter of at least 30 mm were counted. Papillomas
from both PAR2
/ and PAR2
þ /þ animals displayed a
comparable number of large vessels. However, PAR2-
deficient tumors seemed to contain slightly more large blood
vessels. Thus, angiogenesis might be enhanced in these
papillomas.
Additional cell culture experiments using the cell line
HaCaT were performed to analyze signal transduction
pathways activated upon PAR2 stimulation which could
explain, at least in part, the antiproliferative effect of the
receptor in keratinocytes. First, an involvement of the MAPKs
ERK1/2 was found. In contrast, the p38 pathway was not
turned on. The MAPK p38 was reported to be phosphorylated
after PAR2 activation in breast cancer cells (Liu and Mueller,
2006). ERK1/2 were also reported to be phosphorylated upon
PAR2 stimulation in the colon cancer cell line HT-29
(Darmoul et al., 2004). However, receptor activation was
associated with proliferation here. Nevertheless, our findings
are in agreement with an earlier study demonstrating that in
keratinocytes, stimulation of PAR2 caused inhibition of cell
growth, even in the presence of EGF and bovine pituitary
extract (Derian et al., 1997).
It is well known that numerous G-protein-coupled
receptors, including PAR1 and PAR2, are able to transactivate
the EGFR (Prenzel et al., 1999; Sabri et al., 2002; Darmoul
et al., 2004). Transactivation involves shedding of EGFR
ligands (i.e. TGF-a or heparin-binding EGF) from the cell
surface by metalloproteinases, subsequently activating EGFR
in an autocrine/paracrine manner (Prenzel et al., 1999). We
found that PAR2-mediated ERK1/2 phosphorylation in HaCaT
keratinocytes was also fully dependent on EGFR transactiva-
tion, involving tumor necrosis factor-a converting enzyme
and maybe other metalloproteinases.
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Figure 7. PAR2 activation induces TGF-b1 secretion from HaCaT
keratinocytes. After 96 hours, the TGF-b1 content in the medium was 6.1-fold
higher in the presence of tc-AP, compared to the unstimulated control. In
the presence of trypsin, the concentration was enhanced 3.8-fold. After
addition of the MEK1 inhibitor PD98059, TGF-b1 secretion was significantly
inhibited in the presence of trypsin. Interestingly, in the presence of tc-AP,
TGF-b1 secretion was only slightly reduced. In the presence of the scrambled
peptide tc-RP, no induction of TGF-b1 production could be observed. All
experiments were carried out three times. Unst., unstimulated; tc-RP,
tc-RP (104 M); tc-AP, tc-AP (104 M); Trypsin, trypsin (108 M); þ PD,
additional supplementation with PD98059 (10 mM). ***Pp0.001.
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To investigate further a possible secretion of tumor
suppessing factors after PAR2 activation in HaCaT keratino-
cytes, the secretion of TGF-b1 after stimulation with either
trypsin or the PAR2 agonist tc-AP was assessed. TGF-b1 is
well known to be a potent inhibitor of keratinocyte
proliferation (Dahler et al., 2001; Yamasaki et al., 2003).
Indeed, TGF-b1 secretion was significantly stimulated by
activation of PAR2. Thus, we conclude that PAR2 might exert
its antiproliferative effects at least partly through TGF-b1
release via transactivation of EGFR (Figure 8). Moreover, in
the presence of the ERK1/2 pathway inhibitor PD98059,
trypsin-induced secretion of TGF-b1 was inhibited close to
the level of the negative control. Interestingly, TGF-b1
production was only insignificantly reduced in the presence
of PD98059 after stimulation with tc-AP. It might be possible
that tc-AP does not selectively activate PAR2 but one or
several others, yet unidentified receptor(s) on HaCaT cells.
Indeed, McGuire et al. (2002) found this also to be true in
mouse vasculature. Hence, these findings can also be
extended to human cells.
Together, our results clearly show an important role of
PAR2 as a tumor suppressor in the skin, possibly by regulating
K10 expression, suppression of angiogenesis and stimulation
of TGF-b1 secretion.
MATERIALS AND METHODS
Reagents
Chemicals were from Sigma Chemical Co. (Deisenhofen, Germany),
unless otherwise stated. Human PAR2-activating peptide SLIGKV-
NH2 (PAR2-AP), the reverse peptide VKGILS-NH2 (PAR2-RP), trans-
cinnamoyl-LIGRLO-NH2 (tc-AP), and the correlating negative
control trans-cinnamoyl-OLRGIL-NH2 for the activation of PAR2
were synthesized by the Peptide Synthesis Facility of the University
of Calgary, Department of Biochemistry and Molecular Biology,
Canada. EGFR kinase inhibitor PD153035, MMP inhibitors II and III,
tumor necrosis factor-a protease inhibitor-1, and MEK1 inhibitor
PD98059 were obtained from Calbiochem (Schwalbach, Germany).
Human recombinant EGF was purchased from Peprotech
(London, UK).
Mice
Studies were performed in male PAR2-deficient (PAR2
/) and wild-
type (PAR2
þ /þ ) mice (genetic background: C57BL/6 strain) between
8 and 10 weeks of age when starting the carcinogenesis protocol.
Animals were obtained from Charles River Laboratories (Toulouse,
France). All animal experiments were approved by the Animal
Protection Committee of the University Hospital of Mu¨nster.
Chemically induced carcinogenesis
A two-stage skin tumorigenesis protocol was employed, using
DMBA as initiating agent and phorbol myristate acetate (12-O-
tetradecanoylphorbol-13-acetate) as a promoter (Elmets et al, 1998).
To this end, mice were shaved on the back and painted with 100 mg
of DMBA (0.1 % (w/v) stock solution in a mixture of 75 % (v/v)
acetone and 25 % (v/v) olive oil). In addition, 50 mg of DMBA was
applied topically on one ear. Beginning 1 week later, 40 nmol (back)
and 20 nmol (ear) phorbol myristate acetate (800mM stock solution in
acetone/olive oil) was applied biweekly to the sites that had been
treated previously with DMBA. Mice were evaluated weekly for
tumors.
Immunohistochemistry
Normal mouse skin and tumors for cryostat sections were snap-
frozen in liquid nitrogen, embedded in OCT compound (Miles, UK)
and sectioned. Decoration with primary antibodies (polyclonal
rabbit anti-K10, anti-loricrin (all from Covance, Berkeley, CA, USA),
monoclonal rat anti-CD11b (Chemicon, Chandlers Ford, UK),
monoclonal rat anti-CD31 (Cymbus Biotechnology Ltd, Chandlers
Ford, UK) (all dilutions 1:1,000 in 1% (w/v) bovine serum albumin in
phosphate-buffered saline) was performed overnight at 41C. Sections
incubated with monoclonal rat antibodies were subsequently
decorated with biotinylated rabbit anti-rat IgG for 1 hour at room
temperature (RT; 1:1,000 in 1% (w/v) bovine serum albumin/
phosphate-buffered saline; Vector Inc., Burlingame, CA, USA).
Tissues were incubated with EnVision anti-rabbit/horseradish peroxi-
dase-labeled polymer (DakoCytomation, Hamburg, Germany) for
1 hour at RT. Immunoreactions were visualized using the DAB
peroxide substrate kit from DakoCytomation (Hamburg, Germany)
according to the manufacturer’s instructions. Nuclei were counter-
stained with Hematoxylin QS (Vector Inc.). Slides were mounted in
Aquamount (Merck, Darmstadt, Germany) and analyzed with a DM
LB microscope (Leica, Solms, Germany), equipped with a HV-C20M
CCD camera (Hitachi, Rodgau, Germany) and Diskus 4.20 software
(Carl H. Hilgers, Ko¨nigswinter, Germany). For the quantification of
immunohistochemical stainings, three representative pictures were
taken from each papilloma analyzed. Quantification of immuno-
reactivity for K10 was taken out by measuring the number of
K10-positive basal keratinocytes per mm basement membrane.
Immunohistochemical analysis of loricrin was carried out by
counting the loricrin-positive keratinocyte cell layers. Infiltration
with CD11b-positive cells was quantified by counting the cells in a
certain area. Angiogenesis was measured by determining the number
of dermal blood vessels with a diameter of at least 30 mm per mm2
subbasal area.
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Nucleus
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Figure 8. Schematic representation of PAR2-mediated signaling in
keratinocytes. PAR2 is stimulated either by selective proteolytic cleavage or
an activating peptide. This is followed by intracellular calcium mobilization
and activation of tumor necrosis factor-a converting enzyme and maybe other
metalloproteinases that are able to shed EGFR ligands from the cell surface.
Activation of EGFR leads to phosphorylation of ERK1/2 and secretion of
TGF-b1.
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Apoptosis assay
Detection of apoptosis in paraffin sections of mouse papillomas
by TUNEL assay was carried out as described (Scho¨n et al.,
2004).
Cell extraction and immunoblotting
HaCaT cells (kindly provided by Dr. Petra Boukamp, German
Cancer Research Center, Heidelberg, Germany) were cultivated in
10 cm Petri dishes. After 24 hours of serum deprivation, 10 ml
dimethylsulfoxide or the desired inhibitors were added. After
15 minutes of incubation, cells were stimulated for 5 minutes in
the presence of PAR2-AP (10
4
M) or trypsin (107 M). Cells
were extracted by direct lysis with 600 ml hot Laemmli buffer,
scraped off, boiled for 8 minutes, and 10 ml of each extract
were loaded onto a 10% (w/v) polyacrylamide gel. After electro-
phoresis, proteins were transferred to a BA85 nitrocellulose
membrane (Schleicher & Schuell, Dassel, Germany). Membranes
were blocked with 5% (w/v) nonfat dry milk in tris-buffered
saline containing 0.05% (v/v) Tween 20 for 30 minutes at RT.
After washing with tris-buffered saline, membranes were incubated
with first antibodies (anti-phospho-p44/42 MAPK (Thr202/Tyr204;
1:1,000), anti-p44/42 MAPK (1:1,000), both obtained from
Cell Signaling Technology (Frankfurt am Main, Germany)) overnight
at RT. After rinsing with tris-buffered saline, membranes were
decorated with the second antibody (anti-rabbit-horseradish
peroxidase, 1:3,000, Amersham Pharmacia Biotech, Freiburg,
Germany) for 1.5 hours at RT. Immunoreactive bands were
visualized with the Western Lightning chemiluminescence reagent
(PerkinElmer Life Sciences, Rodgau-Ju¨gesheim, Germany) and
exposure to Hyperfilm (Amersham Pharmacia Biotech, Freiburg,
Germany).
TGF-b1 ELISA
HaCaT cells were seeded in six-well plates and grown to confluency.
After 24 hours in the presence of fetal calf serum-free medium, cells
were stimulated with trans-cinnamoyl-OLRGIL-NH2 (10
4
M), tc-AP
(104 M), or trypsin (108 M) in the presence or absence of 10 mM
PD98059. Media were collected on ice after 96 hours and
centrifuged for 5 minutes at 1,500 r.p.m. (41C) in a Heraeus
Megafuge 1.0R (Kendro, Osterode, Germany). Cells were harvested
by trypsinization and counted. ELISA was carried out according to
the manufacturer’s instructions (R&D Systems GmbH, Wiesbaden,
Germany).
Statistics
All results are expressed as means7SEM for a series of experiments.
Differences between data were tested by Student’s t-tests for
unpaired data. Pp0.05 was considered statistically significant.
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